Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4Terminated 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Acrocephalosyndactylia 4Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Solid Tumor 1Recurrence 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Myeloproliferative Disorders 1Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel 1Eosinophilia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pemigatinib 4infigratinib 1erdafitinib 1derazantinib 1atezolizumab 1Rogaratinib 1INCB 54828-101 1Drug Combinations 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Acrocephalosyndactylia × pemigatinib × Clear all
NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Incyte Corporation

Phase 2 Completed
263 enrolled 20 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Incyte Corporation

Phase 2 Completed
147 enrolled 22 charts 1 FDA
Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma

NCT05253807 2025-08-05

FIGHT-210

Incyte Corporation

Phase 2 Completed
8 enrolled 13 charts
Thoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT03235570 2020-05-29

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Incyte Corporation

Phase 1 Completed
44 enrolled

Acrocephalosyndactylia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡